Cancers (Dec 2023)

Radiogenomics: Contemporary Applications in the Management of Rectal Cancer

  • Niall J. O’Sullivan,
  • Hugo C. Temperley,
  • Michelle T. Horan,
  • Alison Corr,
  • Brian J. Mehigan,
  • John O. Larkin,
  • Paul H. McCormick,
  • Dara O. Kavanagh,
  • James F. M. Meaney,
  • Michael E. Kelly

DOI
https://doi.org/10.3390/cancers15245816
Journal volume & issue
Vol. 15, no. 24
p. 5816

Abstract

Read online

Radiogenomics, a sub-domain of radiomics, refers to the prediction of underlying tumour biology using non-invasive imaging markers. This novel technology intends to reduce the high costs, workload and invasiveness associated with traditional genetic testing via the development of ‘imaging biomarkers’ that have the potential to serve as an alternative ‘liquid-biopsy’ in the determination of tumour biological characteristics. Radiogenomics also harnesses the potential to unlock aspects of tumour biology which are not possible to assess by conventional biopsy-based methods, such as full tumour burden, intra-/inter-lesion heterogeneity and the possibility of providing the information of tumour biology longitudinally. Several studies have shown the feasibility of developing a radiogenomic-based signature to predict treatment outcomes and tumour characteristics; however, many lack prospective, external validation. We performed a systematic review of the current literature surrounding the use of radiogenomics in rectal cancer to predict underlying tumour biology.

Keywords